Viking Therapeutics (VKTX) Net Equity Issued and Repurchased (2015 - 2018)

Viking Therapeutics (VKTX) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $165.2 million in Q3 2018.

• For the quarter ending Q3 2018, Net Equity Issued and Repurchased rose 13116.4% year-over-year to $165.2 million; the trailing twelve-month figure through Dec 2018 stood at $238.5 million (up 1072.06% YoY), and the FY2018 full-year result was $296.6 million, up 1226.98% from the prior year.
• Net Equity Issued and Repurchased improved to $165.2 million in Q3 2018, from $58.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $165.2 million in Q3 2018 to a low of $25772.0 in Q3 2016.
• A 4-year average of $28.1 million and a median of $2.5 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased sank 66.33% in 2016 and soared 13116.4% in 2018, its largest moves.
• Tracing VKTX's Net Equity Issued and Repurchased over 4 years: stood at $6.3 million in 2015, then tumbled by 99.59% to $25772.0 in 2016, then surged by 56240.21% to $14.5 million in 2017, then jumped by 1037.78% to $165.2 million in 2018.
• Business Quant data shows VKTX's Net Equity Issued and Repurchased at $165.2 million in Q3 2018, $58.8 million in Q1 2018, and $14.5 million in Q4 2017.